Results 31 to 40 of about 6,571 (189)
Biomedicines, 2023 The repurposing of drugs is one of the most competent strategies for discovering new antimicrobial agents. Vildagliptin is a dipeptidyl peptidase-4 inhibitor (DPI-4) that is used effectively in combination with metformin to control blood glucose levels ...
Maan T. Khayat +7 more
doaj +1 more source
Dipeptidyl Peptidase-4 Inhibitors Associated Heart Failure Events in Adult Patients With Type-2 Diabetes Mellitus Treated With Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis. [PDF]
Endocrinol Diabetes MetabDPP‐4 Inhibitors associated withheart failure events in patients with type‐2 diabetes. This study found statistically insignificant summary effect for all DPP‐4 inhibitors combined but found asignificant association of saxagliptin with heart failure events (RR = 1.24, 95% CI 1.05–1.47). Results are to be interpreted with caution.
Nepal S, Nepal SP.
europepmc +2 more sources
Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
, 2020 Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus.
Magdalena Nowaczewska +5 more
core +1 more source
Voltammetric determination of vildagliptin in a pharmaceutical formulation [PDF]
, 2018 Purpose: To determine vildagliptin concentration in a pharmaceutical formulation using voltammetric analysis techniques, and optimize the parameters affecting the techniques.Method: Four types of voltammetry techniques, including cyclic voltammetry (CV),
Fadr, Muneer +2 more
core +1 more source
Tip 2 diyabet hastalarında vildagliptin tedavisinin portal ven basıncı ve hepatosteatoz üzerine etkisi [PDF]
, 2018 Objective: ftis study investigated how vildagliptin (a di-pepti- dyl peptidase 4 inhibitor) affects portal vein pressure and hepat- osteatosis in patients with type 2 diabetes mellitus.
Çakırca, Mustafa +21 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed +7 more
wiley +1 more source
A case of vildagliptin-induced interstitial pneumonia [PDF]
, 2016 A 65-year-old Japanese male with type 2 diabetes mellitus was admitted to our hospital with a productive cough and worsening dyspnea. He had started receiving vildagliptin, which is one of the dipeptideylpeptidase-4 (DPP-4) inhibitors, several days ...
Kuse, Naoyuki +6 more
core +1 more source
Cardiovascular Diabetology, 2011 Background Progressive remodeling after myocardial infarction (MI) is a leading cause of morbidity and mortality. Recently, glucagon-like peptide (GLP)-1 was shown to have cardioprotective effects, but treatment with GLP-1 is limited by its short half ...
van Gilst Wiek H +4 more
doaj +1 more source
Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients
Frontiers in Endocrinology, 2021 Background and aimsAnimal studies suggested that vildagliptin might exert a beneficial effect on cognitive function. The present study evaluated whether the use of vildagliptin in patients with type 2 diabetes mellitus might affect dementia risk ...
Chin-Hsiao Tseng +2 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang +5 more
wiley +1 more source